Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Core Viewpoint - Immunic, Inc. has successfully closed a registered direct offering of 5,666,667 shares of common stock at a price of $0.90 per share, raising approximately $5.1 million in gross proceeds to fund clinical trials and operations [1][2]. Group 1: Offering Details - The offering was led by Aberdeen Investments and closed on April 10, 2025 [1]. - The gross proceeds from the offering were approximately $5.1 million before deducting commissions and offering expenses [2]. - Titan Partners Group acted as the sole placement agent for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund clinical trials, operations, and other general corporate purposes [2]. Group 3: Company Overview - Immunic, Inc. is a biotechnology company focused on developing orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases [5]. - The lead development program, vidofludimus calcium (IMU-838), is in phase 3 and phase 2 clinical trials for multiple sclerosis and has shown therapeutic activity in earlier trials [5]. - Other development programs include IMU-856, targeting gastrointestinal diseases, and IMU-381, which is in preclinical testing [5].